Business & Industry
- Bayer Foundation announces Science Awards winners of 2024
- GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
- Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
- U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
- Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
Research & Development
- New drug targets for Alzheimer's identified from cerebrospinal fluid
- New weight loss drug target burns energy and lowers appetite - without the nausea and vomiting
- How immune cells "sniff out" pathogens
- New antibody could be promising cancer treatment
- Researchers make glioblastoma cells visible to attacking immune cells
- Scientists discover how specific E. coli bacteria drive colon cancer
- An old drug with new tricks
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy